To provide a pharmaceutical composition effective for ameliorating or treating mental diseases or nervous system diseases developing in relation to the decrease in a physiologically active amine in vivo, such as depression, schizophrenia, panic disorder, Alzheimer's disease and Parkinson's disease.

The pharmaceutical composition contains at least one kind of substance selected from a group consisting of pyridoxamine, pyridoxine, glutathione and their pharmaceutically acceptable salts as an active component.